Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | ACACB | O00763 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18104880 | 0.86 | APP (0.60) | APPMEN1NPC1POLBRAB9A | |
| SCHEMBL4485467 | 0.84 | APP (0.58) | APPMEN1NPC1POLBRAB9A | |
| SCHEMBL11814749 | 0.84 | KDM4E (0.53) | APPMEN1NPC1POLBRAB9A | |
| SCHEMBL6241316 | 0.83 | NPC1 (0.65) | APPMEN1NPC1POLBRAB9A | |
| SCHEMBL9629232 | 0.82 | FFAR1 (0.50) | APPMEN1NPC1RAB9AKMT2A | |
| SCHEMBL17845127 | 0.82 | APP (0.57) | APPMEN1NPC1POLBRAB9A | |
| SCHEMBL13701023 | 0.82 | APP (0.57) | APPMEN1NPC1POLBRAB9A | |
| SCHEMBL10069794 | 0.81 | APP (0.84) | APPMEN1NPC1POLBRAB9A | |
| SCHEMBL27914449 | 0.81 | FFAR1 (0.56) | NPC1FFAR1ACACB | |
| SCHEMBL10069797 | 0.80 | APP (0.72) | APPMEN1NPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1153024-B1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2004-04-28 | — | — | EP | claimed |
| JP-2002537300-A | — | — | 2002-11-05 | — | — | JP | claimed |
| US-20020016329-A1 | 2-Amino-6-anilino-purines and their use as medicaments | NOVARTIS AG (CH) | 2002-02-07 | — | — | US | claimed |
| EP-1153024-A1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2001-11-14 | — | — | EP | claimed |
| WO-2000049018-A1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2000-08-24 | — | — | WO | claimed |
| CN-122059959-A | Synthesis method and application of pyrrolo [2,1-a ] isoquinoline compound | 河南工业大学 | 2026-05-19 | — | — | CN | disclosed |
| US-20230314934-A1 | PHOTOACTIVE COMPOUNDS, PHOTORESIST COMPOSITIONS INCLUDING THE SAME, AND PATTERN FORMATION METHODS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2023-10-05 | — | — | US | disclosed |
| CN-106187969-B | A kind of preparation method of 4- aryl-coumarin class compound | 山东省医学科学院药物研究所 | 2019-03-26 | — | — | CN | disclosed |
| EP-2576488-B1 | PROCESS FOR CIS-1,1,1,4,4,4,-HEXAFLUORO-2-BUTENE | HONEYWELL INT INC (US) | 2018-10-03 | — | — | EP | disclosed |
| CN-104945220-B | Process for the production of fluorinated alkenes | 霍尼韦尔国际公司 | 2017-01-11 | — | — | CN | disclosed |
| CN-105061161-B | A kind of conjugation 1, the preparation method of 3-eneyne derivant | 温州大学 | 2017-01-04 | — | — | CN | disclosed |
| CN-106187969-A | A kind of preparation method of 4 aryl-coumarin compounds | 山东省医学科学院药物研究所 | 2016-12-07 | — | — | CN | disclosed |
| US-6177438-B1 | ANALGESICS, DIURETICS, ANTITUSSIVE AGENTS | TORAY INDUSTRIES, INC. (JP) | 2001-01-23 | — | — | US | disclosed |
| WO-2000024742-A1 | PYRAZOLOPYRIDINE AS ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-05-04 | — | — | WO | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0663401-A1 | MORPHINAN DERIVATIVE AND MEDICINAL USE | TORAY INDUSTRIES, INC. (JP) | 1995-07-19 | — | — | EP | disclosed |
| US-5075488-A | Fungicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-12-24 | — | — | US | disclosed |
| EP-0128006-B1 | A SOIL-DISEASE-CONTROLLING AGENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-09-18 | — | — | EP | disclosed |
| US-4709052-A | FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-11-24 | — | — | US | disclosed |
| EP-0128006-A2 | A soil-disease-controlling agent | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230314934-A1 | PHOTOACTIVE COMPOUNDS, PHOTORESIST COMPOSITIONS INCLUDING THE SAME, AND PATTERN FORMATION METHODS | CRY1, CBR3, C1S | APP 2413/4885MEN1 1410/4885NPC1 2740/4885 |
| US-20020016329-A1 | 2-Amino-6-anilino-purines and their use as medicaments | CDK14, CDK1, CCNB1 | APP 1031/4885MEN1 1981/4885NPC1 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.